Skip to main
HROW

HROW Stock Forecast & Price Target

HROW Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harrow is projected to achieve a revenue of $250M in Q4 of 2027, which may be challenging, but the launch of new products and increased sales of existing ones will contribute to this growth. The recent J-Code approval for IOPIDINE is expected to improve revenue and address a recognized complication in eye procedures. Risks typical to a biotech company exist, but Harrow is focused on meeting their revenue target through continued growth and strategic acquisitions.

Bears say

Harrow is facing some immediate challenges, including a decline in revenue due to high deductible healthcare plans and a gross-to-net problem, but believes these issues will be resolved in the future. In the meantime, their recent expansion of salesforce and upcoming launch of new products like prefilled syringes and a permanent J code for Iopidine may provide some short-term revenue growth. However, there are risks associated with being in the highly competitive and unpredictable pharmaceutical industry.

HROW has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harrow Health Inc (HROW) Forecast

Analysts have given HROW a Strong Buy based on their latest research and market trends.

According to 7 analysts, HROW has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harrow Health Inc (HROW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.